Cyclopamine

Catalog No.S1146 Synonyms: 11-deoxojervine

Cyclopamine Chemical Structure

Molecular Weight(MW): 411.62

Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 370 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • (A)[3H]thymidine incorporation assay of B16F10 melanoma cells treated with DMSO or cyclopamine after incubation with SA-CM from WT and Cav1KO dermal fibroblasts. Representative phase-contrast images of B16F10 cells treated with SA-CM from WT and Cav1KO fibroblasts with cyclopamine are shown on the right. Similar experiments (B) were done with A-375 cells incubated with SA-CM from hTBJ1-shCtrl and hTBJ1-shCAV1 cells.

    Cancer Res 2012 72, 2262-74. Cyclopamine purchased from Selleck.

    (A) The effects of cyclopamine (10 μM) in pancreatic cancer cell invasion. The number of migrated cells was quantified by counting the number of cells from 10 random fields at 200 magnification. (B) The effects of cyclopamine on the expression of EMT-related molecules E-cadherin and vimentin, and Hh pathway-related proteins SMO and Gli-1 were analyzed by Western blotting following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor cyclopamine. Normal culture was used as a negative control. (C) The EMT-related molecules Ecadherin and vimentin mRNA levels, and Hh pathway-related genes at mRNA level were analyzed by real-time RT-PCR following treatment of MiaPaCa-2 and Panc-1 with SDF-1 for 48 h in the presence or absence of the SMO inhibitor Cyclopamine. Normal culture was used as a negative control.

    Cancer Lett 2012 322, 169-176. Cyclopamine purchased from Selleck.

  • Immuofluorescence staining of Gli-1 in MHCC97H cells under normal control or 100 ng/ml CCL2 stimulation or 10 µM Cyc combined with 100 ng/ml CCL2 stimulation for 48 h. Red represents Gli-1 staining. Blue represents nuclear DNA staining by DAPI. Cyc, cyclopamine; CCL2, chemokine (C-C motif) ligand 2.

    Oncol Rep, 2018, 39(1):21-30. Cyclopamine purchased from Selleck.

    (A) Exogenous Shh peptide (500 ng/mL) for 72 hours promoted expansion of CD34+ cells and CD34- cells, cyclopamine (10 μM) for 72 hours induced apoptosis of CD34+ cells and CD34- cells, as measured by 3-(3,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazoliumbromide (MTT) assay, n =4, bars, standard deviation. *Statistically significant compared with CD34+ cells. (B) Exogenous Shh peptide (500 ng/mL) promoted cell expansion after 48 hours and cyclopamine (10 μM) induced cell apoptosis within 24 hours measured by MTT assay (n=6).

    Exp Hematol 2012 40, 418-27. Cyclopamine purchased from Selleck.

  • For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Cyclopamine by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

     

     

    Dr. Yong-Weon Yi from Georgetown University Medical Center. Cyclopamine purchased from Selleck.

Purity & Quality Control

Choose Selective Hedgehog/Smoothened Inhibitors

Biological Activity

Description Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM in TM3Hh12 cells.
Targets
Smoothened [1]
(TM3Hh12 cells)
46 nM
In vitro

Cyclopamine inhibits the Hedgehog signaling pathway with an IC50 of 46 nM, and blocks the activity of human Smo receptor expressed in CHO-K1 cells in [3H]Hh-Ag binding assay with an IC50 of 280 nM. [1] Cyclopamine significantly inhibits Hedgehog pathway activity in a dose-dependent manner in gut-derived tumor cell lines expressing Patched (PTCH) mRNA, and induces growth inhibition of those tumor cell lines by 75-95% at the concentration of 3 μM, but ineffective towards the colon tumor cells without PTCH mRNA expression, suggesting the effects of Cyclopamine treatment are Hedgehog pathway related rather than generally cytotoxic. [2] By blocking Hedgehog signaling through direct interaction with Smo, Cyclopamine (10 μM) inhibits the proliferation of SMOhigh Cyclopamine-responsive cell lines L3.6sl and Panc 05.04 by 75-80%, and increases the apoptosis by 2.5- to 3.5-fold, without affecting the BxPC3-SMOlow cell line. [3] Cyclopamine treatment significantly decreases of Snail mRNA and increasea E-cadherin transcripts in the E3LZ10.7 cell line. Independent of inhibition of cell growth, Cyclopamine treatment significantly inhibits the invasive phenotype of Hedgehog-dependent L3.6pl cells, causing a >500-fold reduction in the number of transmigrating cells, but not that of the Hedgehog-independent cell line Panc-1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OS-RC-2 M1fQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;uSmlEPTB;NT64OlY3KM7:TR?= NH\SXo5USU6JRWK=
DOHH-2 NYXTeGg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvzbYdKSzVyPUmuN|U3QDlizszN NWLQZpl[W0GQR1XS
no-10 NXzxSGhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17xRWlEPTB;OT65NFM6KM7:TR?= Mof5V2FPT0WU
LS-513 Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT2W29KSzVyPUGxMlM2PDdizszN MV7TRW5ITVJ?
ALL-PO MkPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnewTWM2OD1zMT63O|M1KM7:TR?= MnvEV2FPT0WU
8-MG-BA MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M160TWlEPTB;MUOuNVEzOyEQvF2= MWDTRW5ITVJ?
RPMI-8402 M3Wycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr1XG9KSzVyPUG1Mlg2OzdizszN M2TFcnNCVkeHUh?=
EoL-1-cell MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXxTWM2OD1zOD61PVQ5KM7:TR?= NVX4boN4W0GQR1XS
NALM-6 M1\Nemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF7LkCxOlch|ryP MWXTRW5ITVJ?
DEL NHO1UG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJyLkG0O|Eh|ryP NYfZeIp3W0GQR1XS
SR NHfqV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTHN5ByUUN3ME2yN{43PzF3IN88US=> MlOyV2FPT0WU
697 M13xT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTTeGdKSzVyPUK2MlYyPTVizszN MnHxV2FPT0WU
COLO-829 MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33Mb2lEPTB;Mk[uPFQ5OyEQvF2= MoDHV2FPT0WU
EVSA-T NEDYS4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjDSZBKSzVyPUK3MlU2PjFizszN MVjTRW5ITVJ?
ATN-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLaTHVUUUN3ME2zNU4zOzJ7IN88US=> MVjTRW5ITVJ?
L-363 Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTNzLke0OlEh|ryP NUToU2FDW0GQR1XS
LAMA-84 NUfCSW1OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf5TWM2OD1|Mj61NlEyKM7:TR?= MorWV2FPT0WU
NOS-1 M3\vfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLiVm1ZUUN3ME2zOE4zQTV4IN88US=> NGHTb|NUSU6JRWK=
BB30-HNC MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPk[olkUUN3ME2zOE4{OzB4IN88US=> NHS2VldUSU6JRWK=
BC-1 MlPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHkbpJNUUN3ME2zO{46PzR4IN88US=> NIr6dZBUSU6JRWK=
IST-SL2 MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC2dGZKSzVyPUO4MlIzPCEQvF2= NIDmTZdUSU6JRWK=
D-392MG NXLBTmdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHj1e5RKSzVyPUSwMlIzOTVizszN M1W4b3NCVkeHUh?=
no-11 MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LzdmlEPTB;NECuOVUzOSEQvF2= NXLOV|V7W0GQR1XS
LC4-1 MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofBTWM2OD12MD64O|E3KM7:TR?= MkjDV2FPT0WU
A388 M1LIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fFT2lEPTB;NEKuOVg1QCEQvF2= NGTncGFUSU6JRWK=
NTERA-S-cl-D1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHYTWM2OD12Mj63NFc1KM7:TR?= MVrTRW5ITVJ?
CESS NGrkUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLtUJVuUUN3ME20OE4zOjN{IN88US=> NFjsWlNUSU6JRWK=
RS4-11 NVf6UJR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTNRnRKSzVyPUS5MlA6OzhizszN MoqyV2FPT0WU
MS-1 M4r0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLMTWM2OD13MD65N|UyKM7:TR?= NEXmXFdUSU6JRWK=
CTV-1 NV3USWVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDKZ2hKSzVyPUWxMlA4PCEQvF2= NX3jOY9JW0GQR1XS
D-502MG M4LsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLrVGJrUUN3ME21NU43OjdzIN88US=> NHL2U2ZUSU6JRWK=
ML-2 MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;Xb282UUN3ME21Nk46OTl3IN88US=> NXS3TYJ1W0GQR1XS
SK-NEP-1 MmXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2SxS2lEPTB;NUOuN|kzOyEQvF2= M2f6VXNCVkeHUh?=
LOXIMVI NF\1OllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTV|LkW4PFQh|ryP MlrRV2FPT0WU
DJM-1 NUDwPIUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfxUoNKSzVyPUW2MlM{QTFizszN M2L0UXNCVkeHUh?=
GI-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPOTWM2OD13Nj62NVQ6KM7:TR?= M1fYc3NCVkeHUh?=
IST-MES1 NFThOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUj4elNQUUN3ME22NE42PDl|IN88US=> M2\C[XNCVkeHUh?=
MV-4-11 MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17JW2lEPTB;NkCuOlU{QCEQvF2= NVS4TmhxW0GQR1XS
OVCAR-4 M1e2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTuNVFxUUN3ME22N{42PjV5IN88US=> MX;TRW5ITVJ?
KE-37 MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTZ4LkK2Olgh|ryP NYHXfWd3W0GQR1XS
D-542MG M33tPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XadWlEPTB;NkiuOFE{PSEQvF2= NF\5XYZUSU6JRWK=
MHH-PREB-1 M{\ycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LSW2lEPTB;N{KuPFQ1OSEQvF2= NXrBXGFzW0GQR1XS
MRK-nu-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj5TWM2OD15Mz60O|A2KM7:TR?= MnLYV2FPT0WU
D-247MG M{fuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;nTWM2OD15Mz61OFQzKM7:TR?= M4rqenNCVkeHUh?=
OCI-AML2 NFTIbnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnlTWM2OD15Nj65N|Y6KM7:TR?= MoXJV2FPT0WU
LP-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrZPXhuUUN3ME24Nk45PzNzIN88US=> M33aWHNCVkeHUh?=
HCC1599 NFK1c2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTh2LkK4N|ch|ryP MWrTRW5ITVJ?
KARPAS-45 NIPRb3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDRR49KSzVyPUi0MlY6QTJizszN MWnTRW5ITVJ?
BE-13 M1vxRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrETWM2OD17OT6wOFc4KM7:TR?= M3PqcXNCVkeHUh?=
GCIY MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHm2T4RKSzVyPUm5MlA6PTRizszN NWnhephQW0GQR1XS
BV-173 MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P4fGlEPTB;MUCwMlMzPSEQvF2= M{\qd3NCVkeHUh?=
LB2518-MEL NX3Fc4tFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3mydmlEPTB;MUCwMlc5QSEQvF2= NGjKN5FUSU6JRWK=
KS-1 NEnqOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTFyMT62N|kh|ryP M2HadHNCVkeHUh?=
MOLT-16 NIDmbnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XMRWlEPTB;MUC0Mlk5PiEQvF2= MXTTRW5ITVJ?
NCI-H1770 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\GXXN6UUN3ME2xNFgvPzh2IN88US=> MVnTRW5ITVJ?
NCI-H82 M3;WOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjwVpo{UUN3ME2xNVAvQTd4IN88US=> M3qwXXNCVkeHUh?=
NCCIT MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{P2WGlEPTB;MUGyMlUzQSEQvF2= MXjTRW5ITVJ?
KALS-1 MojOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWzTWM2OD1zMUWuPVQyKM7:TR?= NYrmUnJlW0GQR1XS
LB2241-RCC NVLrV5BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7acIlGUUN3ME2xNVYvPjd7IN88US=> NVnwNoZ2W0GQR1XS
HH NILBWXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvMTWM2OD1zMUeuN|k2KM7:TR?= NUfLXpdDW0GQR1XS
HD-MY-Z NWnPfIZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFzOD60PFgh|ryP MWfTRW5ITVJ?
EB-3 M37MUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fWSGlEPTB;MUKzMlA6PCEQvF2= NWrzbZh{W0GQR1XS
BL-70 M3TaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTF{Mz6xNlch|ryP NVvIVpBRW0GQR1XS
K-562 NGfTU|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7BTWM2OD1zMk[uNlQ2KM7:TR?= M2rp[nNCVkeHUh?=
HT-144 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF|Mz6xOlQh|ryP M1i5UnNCVkeHUh?=
PF-382 NVLvXJJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonoTWM2OD1zM{SuN|YyKM7:TR?= NX;POpBrW0GQR1XS
RPMI-8226 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH0TWM2OD1zM{WuNFQ2KM7:TR?= M2izS3NCVkeHUh?=
NCI-H1355 NXq1SIxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrofmxKSzVyPUGzOU42QDdizszN MkTuV2FPT0WU
LXF-289 NHu3bFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTF|OT63PFEh|ryP M4[2SnNCVkeHUh?=
NCI-H69 NWDvcnBvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PZdGlEPTB;MUSyMlk{OiEQvF2= MoPJV2FPT0WU
SK-MEL-1 NXXnRYhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\mWoxOUUN3ME2xOFcvOTNizszN MlTvV2FPT0WU
KARPAS-299 M3HGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkj6TWM2OD1zNEmuNVIh|ryP NYezcHhsW0GQR1XS
GB-1 NIja[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF2OT6zNlIh|ryP MlXwV2FPT0WU
CMK MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M32wemlEPTB;MUS5MlUyPSEQvF2= MXrTRW5ITVJ?
MPP-89 MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[0c4RKSzVyPUG1Ok4xOzVizszN NF7udHpUSU6JRWK=
KU812 NV62XWtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTRTWM2OD1zNkGuPVAzKM7:TR?= M3fNOXNCVkeHUh?=
REH MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTF4Mj6xNlUh|ryP M1H1dXNCVkeHUh?=
NEC8 Mo[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Lpd2lEPTB;MU[1MlAzPiEQvF2= MlTnV2FPT0WU
KP-N-YS NV70d5FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDYTWM2OD1zNkiuN|k2KM7:TR?= MlThV2FPT0WU
Ramos-2G6-4C10 M1uybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\wU5RKSzVyPUG2PU46OTVizszN NW\FW2NTW0GQR1XS
Becker MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:3Z21KSzVyPUG3OE4yQCEQvF2= M1u0NHNCVkeHUh?=
LB647-SCLC Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTHTWM2OD1zN{WuPFQ2KM7:TR?= NG\6RYxUSU6JRWK=
LU-139 Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrJbIFKSzVyPUG3PE4xOTlizszN MY\TRW5ITVJ?
QIMR-WIL MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7VOGZKSzVyPUG3PU43PDZizszN NUjmSI1IW0GQR1XS
NCI-H1395 NEHLSmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF5OT65PVYh|ryP M1f2N3NCVkeHUh?=
NOMO-1 NHK0cYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTF6Mj64OUDPxE1? MnHWV2FPT0WU
GI-ME-N M3XNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDn[|VKSzVyPUG4O{46PjlizszN MmG5V2FPT0WU
KMS-12-PE NHrldHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPWbVZzUUN3ME2xPFkvOjd|IN88US=> MXLTRW5ITVJ?
Daudi MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDE[GpKSzVyPUG5NU4yOjhizszN NH\IfVVUSU6JRWK=
LB996-RCC M1PacWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj2TWM2OD1zOUGuOlk6KM7:TR?= NInsOoVUSU6JRWK=
NCI-H2107 NHr2OFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHexdmFKSzVyPUG5N{44OzlizszN MonoV2FPT0WU
SK-PN-DW M4TNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlj3TWM2OD1zOUSuO|E6KM7:TR?= NEfRc3BUSU6JRWK=
MC-CAR MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT2TWM2OD1{MEKuNlU{KM7:TR?= M4PmcHNCVkeHUh?=
SNB75 M2HsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jhUWlEPTB;MkKxMlk1KM7:TR?= MUDTRW5ITVJ?
ES4 MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe5NpN1UUN3ME2yNlMvPzh|IN88US=> Mmj5V2FPT0WU
KARPAS-422 M3jLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\hSo1KSzVyPUKyPE4{PTJizszN NF3kepBUSU6JRWK=
NCI-H1648 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml60TWM2OD1{MkmuOFg6KM7:TR?= NUfiWoJJW0GQR1XS
ES6 M4C3R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDmSG1KSzVyPUKzPU41OyEQvF2= M163R3NCVkeHUh?=
KNS-81-FD NX;0WYZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJ2MT6xPVch|ryP MXvTRW5ITVJ?
JAR NH74d3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrDNVQ2UUN3ME2yOVYvOjJ3IN88US=> NGmyeYRUSU6JRWK=
NB1 MkeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonHTWM2OD1{NkCuOVE3KM7:TR?= NFvV[nlUSU6JRWK=
D-336MG M1jSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TmOWlEPTB;Mk[wMlY6QCEQvF2= NXPkRllRW0GQR1XS
BC-3 NXfSNlZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jPb2lEPTB;Mk[1MlE4QCEQvF2= NYjlTldnW0GQR1XS
HCC2218 M2HqUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LWTWlEPTB;Mk[2MlQyPSEQvF2= NFvPZohUSU6JRWK=
TE-9 NGjnSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3UTWM2OD1{Nk[uOlI4KM7:TR?= MXHTRW5ITVJ?
LB1047-RCC MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD5TWM2OD1{Nk[uO|U{KM7:TR?= Mk\EV2FPT0WU
CTB-1 M3fHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrSbWxVUUN3ME2yOlkvQTd|IN88US=> M3THTnNCVkeHUh?=
NB7 NFPVd49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzoTWM2OD1{N{Gg{txO MknwV2FPT0WU
ST486 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3y4UGlEPTB;Mke3MlQyOiEQvF2= M{fJOnNCVkeHUh?=
HCC1187 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnqRZo3UUN3ME2yPFIvQDFzIN88US=> NXH4Z4cxW0GQR1XS
NCI-SNU-16 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLqOXBCUUN3ME2yPFQvOjR6IN88US=> NFPpTGdUSU6JRWK=
COR-L279 NFS4VIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLsTWM2OD1{OUGuOVg1KM7:TR?= MV\TRW5ITVJ?
ES8 NFraeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjvcopFUUN3ME2yPVQvOTh{IN88US=> NX;LTJhwW0GQR1XS
U-698-M MkfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJ7OD6yOFMh|ryP MXnTRW5ITVJ?
HEL NUfxWZJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTNyOT6xOFkh|ryP NYXEXHFlW0GQR1XS
KINGS-1 M{e5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHscpNKSzVyPUOxNE43PzRizszN MX3TRW5ITVJ?
KY821 NVzYTIdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTN|Nj61PVUh|ryP NX3NfYhQW0GQR1XS
MZ1-PC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoOzTWM2OD1|NEWuOlE5KM7:TR?= NHPDPWlUSU6JRWK=
LS-411N NEnhXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojlTWM2OD1|NUSuOlYh|ryP NX\4W|IyW0GQR1XS
SIG-M5 M4TVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofRTWM2OD1|NUmuO|gzKM7:TR?= NFnXTGtUSU6JRWK=
HT NV64XIRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTN4Nz63NVEh|ryP M3mweHNCVkeHUh?=
HC-1 MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Th[mlEPTB;M{[3Mlc5PyEQvF2= MWPTRW5ITVJ?
NCI-H1694 NIDEb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;ufJlKSzVyPUO3Nk46OzRizszN MkLaV2FPT0WU
BB65-RCC NV34dGNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTKcFhKSzVyPUO3Ok4zPDVizszN MWXTRW5ITVJ?
HAL-01 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTN5OT64N|gh|ryP M4DvdHNCVkeHUh?=
ARH-77 MlfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLo[XM4UUN3ME2zPVQvODB6IN88US=> M{nGUXNCVkeHUh?=
MZ7-mel NY\qcldXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr5PFJKSzVyPUO5O{4zOzNizszN MYTTRW5ITVJ?
SIMA M3LPbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILWS4xKSzVyPUSwN{46OzNizszN NIDUR5ZUSU6JRWK=
DG-75 M2T4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljITWM2OD12MUWuOlk5KM7:TR?= M4L1fHNCVkeHUh?=
HUTU-80 NFPrW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTRzOT6xPFUh|ryP NHrFWlZUSU6JRWK=
KNS-42 MorpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTQ[nFyUUN3ME20NlUvQDF3IN88US=> NYSze2l5W0GQR1XS
SH-4 MmThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7VTWM2OD12MkeuOVY2KM7:TR?= M4H2e3NCVkeHUh?=
L-540 M17RS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j0PGlEPTB;NEOxMlA{OSEQvF2= MlWzV2FPT0WU
NB10 NHizfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTR2MT6yN|Qh|ryP MYLTRW5ITVJ?
ES1 NX\rc3pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HBdGlEPTB;NEWyMlc2OyEQvF2= MljTV2FPT0WU
KMOE-2 MkTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PmcmlEPTB;NEW2MlcyOSEQvF2= MYXTRW5ITVJ?
MC116 NUDyS2pLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{myUGlEPTB;NEW4MlEyPiEQvF2= M4jv[3NCVkeHUh?=
RCC10RGB NGjwVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TKd2lEPTB;NE[wMlAxPSEQvF2= MVzTRW5ITVJ?
RL95-2 MlLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDQN2dKSzVyPUS2NE4zOzdizszN M4Lxe3NCVkeHUh?=
Raji NFjyZVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkGxTWM2OD12NkiuNVQ{KM7:TR?= NWiyRVZSW0GQR1XS
CAS-1 NUm2e2o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7xVVhKSzVyPUS3Nk4xPzNizszN MlnKV2FPT0WU
Calu-6 NX;UXVN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHqSXRTUUN3ME20O|UvOjZ3IN88US=> M3fDWXNCVkeHUh?=
KG-1 Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTR5OD60OEDPxE1? NXK0fWEzW0GQR1XS
LB771-HNC M3m3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjKeVJKSzVyPUS4Nk4zOzJizszN NXHZbIxxW0GQR1XS
ACN M{DLdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTR7Mz61PVkh|ryP NITyN4VUSU6JRWK=
KM12 NVm2OW5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDDOmRXUUN3ME20PVYvPTh7IN88US=> MVnTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Administration of Cyclopamine at dose of 50 mg/kg/day for 22 days eradicates the HUCCT1 xenografts in mice with no obvious adverse effects. [2] Cyclopamine treatment at dose of 1.2 mg for 7 days induces significant apoptosis of tumor cells and decreases the tumor mass by 50-60% in Panc 05.04- and L3.6sl-derived tumors, respectively, but not in the BxPC3-SMOlow tumors. [3] Administration of Cyclopamine alone profoundly inhibits tumor metastases in xenografts of E3LZ10.7 and L3.6pl, and completely abrogates metastases when in combination of gemcitabine. [4]

Protocol

Kinase Assay:[1]
+ Expand

Hedgehog cell assay:

This assay measures the end stage of the Hh signaling pathway, that is, the transcriptional modulation of Gli, using Luciferase as readout (Gli-Luc assay). Cyclopamine is prepared for assay by serial dilution in DMSO and then added to empty assay plates. TM3Hh12 cells (TM3 cells containing Hh-responsive reporter gene construct pTA-8xGli-Luc) are resuspended in F12 Ham's/DMEM (1:1) containing 5% FBS and 15 mM Hepes pH 7.3, added to assay plates and incubated with Cyclopamine for approximately 30 minutes at 37 °C in 5% CO2. 1 nM Hh-Ag 1.5 is then added to assay plates and incubated at 37 °C in the presence of 5% CO2. After 48 hours, either Bright-Glo or MTS reagent is added to the assay plates and luminescence or absorbance at 492 nm is determined. IC50 value, defined as the inflection point of the logistic curve, is determined by non-linear regression of the Gli-driven luciferase luminescence or absorbance signal from MTS assay vs log10 (concentration) of Cyclopamine using the R statistical software pack
Cell Research:[2]
+ Expand
  • Cell lines: SEG1, OE33, KYAE, KYSE180, SNU1, AGS, SNU16, NCI-N-87, HUCCT1, PANC1, PL5, PL6, BXPC3, HS766T, KYSE150, GBD1, DLD1, and HCT116
  • Concentrations: Dissolved in DMSO, final concentration 3 μM
  • Incubation Time: 4 days
  • Method: Cells are exposed to Cyclopamine in 96-well plates. Cell viability is measured by MTS (soluble tetrazolium salt) assay. Viable cell mass is determined by optical density measurements at 490 nm (OD490) at 2 and 4 days using the CellTiter96 colorimetric assay. Relative growth is calculated as OD (day 4)﹣OD (day 2)/OD (day 2).
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Athymic (nude) mice inoculated subcutaneously with HUCCT1 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 50 mg/kg/day
  • Administration: Subcutaneous injection
    (Only for Reference)

Solubility (25°C)

In vitro DMF 10 mg/mL warmed (24.29 mM)
Ethanol 2 mg/mL warmed (4.85 mM)
DMSO Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 411.62
Formula

C27H41NO2

CAS No. 4449-51-8
Storage powder
in solvent
Synonyms 11-deoxojervine

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo use in mice?

  • Answer:

    One paper dissolved this drug in DMSO, and diluted in saline: Berman DM, et al. Nature, 2003, 425(6960), 846-851. Alternatively, you can try this vehicle: 10% DMSO+30% PEG 300+5% Tween 80+ddH2O for P.O. When preparing the solution, please dissolve the compound in DMSO clearly first. Then add PEG300 and Tween, after they mixed well, dilute with water.

Hedgehog/Smoothened Signaling Pathway Map

Hedgehog/Smoothened Inhibitors with Unique Features

Related Hedgehog/Smoothened Products4

Tags: buy Cyclopamine | Cyclopamine supplier | purchase Cyclopamine | Cyclopamine cost | Cyclopamine manufacturer | order Cyclopamine | Cyclopamine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID